Radezolid

Radezolid

Skeletal formula of radezolid
Systematic (IUPAC) name
N-{[(5S)-3-(2-fluoro-4′-{[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
Clinical data
Legal status	Investigational
Routes of administration	Intravenous infusion, oral
Identifiers
CAS Number	869884-78-6
ATC code	none
PubChem	CID: 11224409
ChemSpider	9399462
UNII	53PC6LO35W Y
ChEMBL	CHEMBL455461
Chemical data
Formula	C22H23FN6O3
Molecular mass	438.455 g/mol
SMILES CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(c2)F)c3ccc(cc3)CNCc4cnn[nH]4

Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).

External links

• Radezolid at Rib-X Pharmaceuticals